What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
Short answer: Menopausal hormone therapy (HT) is the most effective treatment for hot flashes and night sweats, and systemic HT prevents bone loss and lowers fracture risk while it is used. It is not recommended as a way to prevent heart disease or other chronic conditions in people without symptoms. Whether HT is reasonable depends on your age, time since menopause, symptoms, uterus status, route and dose, medical history, family history, and preferences. A clinician should review those factors before you start, stop, or change treatment.
What menopausal hormone therapy can—and cannot—do
Menopausal hormone therapy supplies estrogen, with a progestogen added for most people who still have a uterus. It can be systemic (reaching the bloodstream through a pill, patch, gel, spray, injection, or other formulation) or local (low-dose vaginal estrogen placed in the vagina for genitourinary symptoms). These are different treatments with different exposure and risk discussions.
As an Amazon Associate I earn from qualifying purchases.
The Menopause Society describes hormone therapy as the most effective treatment for vasomotor symptoms—hot flashes and night sweats—and for the genitourinary syndrome of menopause, which can include vaginal dryness, irritation, painful sex, urinary urgency, or recurrent urinary symptoms. Systemic HT also prevents bone loss and has been shown to reduce fractures. Those benefits do not make HT a cardiovascular-prevention drug.
Free tools Windows power users keep installed
One-click scans. No signup required.
The distinction matters:
- Symptom treatment: HT may be appropriate when symptoms are bothersome and there is no contraindication.
- Bone protection: Systemic HT can prevent bone loss and reduce fractures, but osteoporosis risk still requires an individualized assessment.
- Primary prevention in an asymptomatic person: The U.S. Preventive Services Task Force (USPSTF) recommends against using systemic estrogen plus progestin, or systemic estrogen alone after hysterectomy, to prevent chronic conditions.
The USPSTF recommendation does not address treatment of menopause symptoms. It also does not apply to premature ovarian insufficiency or surgical menopause, situations in which estrogen deficiency can begin unusually early and the balance of benefits and risks is different.
#1 Best Overall
- Read Before You Buy — No Video Output: These adapters support charging and USB 2.0 data transfer, but cannot transmit video signals. Except for standard USB webcams (which use USB data only), they are not compatible with HDMI/DisplayPort cables, video-capable USB-C hubs, or docking stations with video output.
- Convert USB-A Ports to USB-C: Designed to connect USB-C earphones, cables, flash drives, card readers, and other USB-C accessories to standard USB-A ports. Plug-and-play with no drivers or software required.
- Aluminum Alloy Housing: Built with a sturdy aluminum alloy shell that aids in heat dissipation and protects against daily wear and scratches. Designed to maintain a stable and secure connection.
- Compact & Travel-Friendly: The ultra-compact design allows the adapter to stay plugged into your device without blocking adjacent ports or adding bulk, reducing wear and tear on your original USB ports.
- 12-Month Warranty: Backed by a 12-month manufacturer warranty for peace of mind. Designed to meet strict quality control standards for reliable everyday performance.
Does hormone therapy prevent heart disease?
No. HT should not be started solely to prevent a first heart attack, stroke, or other cardiovascular disease. The Menopause Society’s 2024 statement says estrogen-containing HT is not recommended for primary cardiovascular prevention in people who reach menopause at the average age. The USPSTF found no net benefit for primary prevention of chronic conditions in asymptomatic postmenopausal people.
Timing and personal characteristics can influence cardiovascular outcomes. Professional guidance generally finds a more favorable overall benefit-risk balance for many healthy, symptomatic people who begin systemic HT before age 60 or within 10 years of menopause onset. That timing concept is used to discuss treatment of symptoms; it is not a prescription to use HT as heart prevention and it does not override a contraindication.
Do not turn observational studies or subgroup findings into a promise that HT protects the heart. Heart-risk assessment should instead address established measures such as blood pressure, cholesterol, diabetes, smoking, physical activity, sleep, weight, and family history. If cardiovascular disease is already present, a clinician—often with menopause or cardiology expertise—should review whether systemic HT is suitable at all.
The large Women’s Health Initiative (WHI) trial formulation cited by the USPSTF used 0.625 mg per day of oral conjugated equine estrogen, with or without 2.5 mg per day of medroxyprogesterone acetate. Those doses and products describe that trial; they are not a recommended dose or a model for every current patch, gel, spray, pill, or progestogen.
Can hormone therapy prevent osteoporosis?
Yes, systemic HT prevents bone loss and lowers fracture risk. Bone protection is one of the FDA-approved uses described by the USPSTF, alongside treatment of menopausal symptoms. Estrogen slows the rapid bone turnover that follows ovarian estrogen decline, so bone density commonly falls more slowly while therapy continues.
Rank #2
- 5-in-1 USB-C Hub: Experience comprehensive connectivity featuring a Power Delivery input, two USB-A 2.0 ports, a USB-A 3.0 port, and an HDMI port. (Note: The USB-C power delivery input port is only for connecting an external wall charger to power your laptop and cannot power peripheral devices.)
- 90W Pass-Through Charging: Achieve optimal charging with 90W pass-through power to your laptop, supported by a total input of 100W, with the hub reserving 10W for operational efficiency. (Note: Wall charger not included.)
- Quick Data Transfers: Accelerate your productivity with rapid data transfers using a high-speed 5Gbps USB 3.0 port and two 480Mbps USB 2.0 ports.
- 4K HDMI Display: Enhance your visual experience with a hub capable of delivering 4K resolution at 30Hz in both mirror and extend modes. Please note that this hub is compatible with MacBook (macOS 12 and newer), Windows 10 and 11, ChromeOS, and laptops equipped with DP Alt Mode and Power Delivery. Note: This device is not compatible with Linux.
- What You Get: Anker USB-C Hub (5-in-1, 4K HDMI), welcome guide, 18-month warranty, and our friendly customer service.
That does not mean HT is the right osteoporosis treatment for everyone. The decision depends on bone-density results, prior or current fractures, age, fall risk, kidney and gastrointestinal health, cancer history, other medicines, and the person’s preferences. Someone with diagnosed osteoporosis may have medicines specifically studied for fracture reduction that are more appropriate than HT, particularly if there are no troublesome menopause symptoms.
ACOG’s Clinical Practice Guideline No. 2, “Management of Postmenopausal Osteoporosis” (April 2022, reaffirmed 2026), addresses pharmacologic options, monitoring, follow-up, and the roles of calcium and vitamin D. Ask a clinician whether you need a bone-density scan and a formal fracture-risk calculation rather than choosing supplements or hormones on your own.
Recommended Free Tools
When is the benefit-risk balance usually more favorable?
For many healthy people with moderate-to-severe symptoms, professional guidance says benefits generally outweigh risks when systemic HT starts before age 60 or within 10 years after menopause begins, after individualized counseling. This is a population-level framework, not a guarantee of safety for a particular person.
Natural menopause occurs at a median age of 51.3 years, according to the USPSTF. Age alone is not a treatment threshold: time since the final menstrual period, symptom severity, uterus status, route, dose, and health history all matter.
Early menopause and primary ovarian insufficiency
Menopause before the usual age and primary ovarian insufficiency (loss of ovarian function before age 40) deserve separate consideration. The Menopause Society’s 2022 position statement notes higher risks of bone loss and cardiovascular disease associated with prolonged estrogen deficiency and recommends considering HT until at least the mean age of menopause unless contraindicated. That advice should not be casually generalized to typical-age menopause; the diagnosis, cause, age, and risks need confirmation.
Rank #3
- Sleek 7-in-1 USB-C Hub: Features an HDMI port, two USB-A 3.0 ports, and a USB-C data port, each providing 5Gbps transfer speeds. It also includes a USB-C PD input port for charging up to 100W and dual SD and TF card slots, all in a compact design.
- Flawless 4K@60Hz Video with HDMI: Delivers exceptional clarity and smoothness with its 4K@60Hz HDMI port, making it ideal for high-definition presentations and entertainment. (Note: Only the HDMI port supports video projection; the USB-C port is for data transfer only.)
- Double Up on Efficiency: The two USB-A 3.0 ports and a USB-C port support a fast 5Gbps data rate, significantly boosting your transfer speeds and improving productivity.
- Fast and Reliable 85W Charging: Offers high-capacity, speedy charging for laptops up to 85W, so you spend less time tethered to an outlet and more time being productive.
- What You Get: Anker USB-C Hub (7-in-1), welcome guide, 18-month warranty, and our friendly customer service.
Why uterus status changes the regimen
Systemic estrogen stimulates the endometrium, the lining of the uterus. If you have a uterus, adequate progestogen is generally required to reduce endometrial hyperplasia and cancer risk. Estrogen-only therapy is a different risk-benefit situation after a total hysterectomy, although the type of surgery and any residual endometrial tissue still matter.
| Situation | Typical discussion | Important qualification |
|---|---|---|
| Uterus present | Systemic estrogen plus a progestogen is generally considered. | The dose, schedule, and progestogen must provide adequate endometrial protection; unexpected bleeding needs evaluation. |
| Total hysterectomy | Systemic estrogen alone may be considered when indicated. | The surgical history and reason for hysterectomy affect the decision. |
| Genitourinary symptoms only | Low-dose vaginal estrogen is a local option. | It is not equivalent to systemic dosing; product labeling and personal cancer history still need review. |
Systemic versus local treatment, route, and dose
Systemic HT is available orally and through transdermal products such as patches, gels, and sprays. The Menopause Society’s 2022 statement says transdermal routes and lower doses may reduce venous thromboembolism and stroke risk compared with some oral regimens. “May reduce” is a relative-risk statement, not a claim that a patch, gel, or low dose is risk-free.
| Option | Best fit to discuss | What it does not establish |
|---|---|---|
| Oral systemic estrogen | Whole-body treatment for hot flashes and other systemic symptoms. | It is not automatically safer or less safe for every person; clot, stroke, liver, and cardiovascular factors matter. |
| Transdermal systemic estrogen (patch, gel, spray) | Systemic symptom treatment when a clinician wants to consider a route associated with lower clot or stroke risk in some guidance. | No route eliminates contraindications or all vascular risk. |
| Systemic estrogen plus progestogen | People with a uterus who need systemic estrogen. | The regimen must be individualized; breast and endometrial risks vary by formulation and duration. |
| Low-dose vaginal estrogen | Dryness, burning, painful sex, and some urinary symptoms confined mainly to the genitourinary tract. | It is not a substitute for systemic treatment of hot flashes or for systemic bone protection. |
Use the lowest effective dose for the treatment goal, and reassess periodically with the prescriber. Do not stop abruptly, switch routes, or alter a progestogen schedule without medical advice.
What are the important risks and contraindications?
Risk is not one fixed percentage for all HT. It changes with formulation, dose, route, duration, age, time since menopause, and medical history. The Menopause Society and related guidance discuss the following concerns:
- Blood clots and stroke: Systemic therapy can affect venous thromboembolism and stroke risk; route and dose matter.
- Endometrial cancer: In a person with a uterus, estrogen without adequate progestogen can cause endometrial overgrowth and cancer.
- Breast cancer: Risk depends on the estrogen-progestogen regimen, duration, and personal and family history; it cannot be summarized with one number for every product.
- Cardiovascular disease: Existing coronary disease, stroke, or substantial risk may make systemic HT unsuitable or require specialist review.
- Liver disease: Active or significant liver disease can change whether systemic therapy is appropriate.
- Unexplained vaginal bleeding: Bleeding requires evaluation before starting or continuing systemic HT.
- Prior hormone-sensitive cancer or clotting events: A history of breast or uterine cancer, venous clot, or pulmonary embolism warrants specialist assessment and may rule out systemic HT.
Seek urgent care for chest pain, sudden shortness of breath, coughing blood, one-sided leg swelling, sudden weakness, trouble speaking, or a severe new headache. Report any postmenopausal bleeding promptly, even if it occurs after months on a stable regimen.
The Tool Desk
Outbyte PC Repair FREEClear out junk files and repair common Windows errorsFree Scan →Outbyte Driver Updater FREEScan for outdated or missing drivers - takes under a minuteDriver Scan →Rank #4
- Dual Converters, Infinite Potential：Includes 2× USB C male to USB A female adapters and 2× USB A male to USB C female adapters. Perfect for a wide range of uses—tablets with Bluetooth keyboards, expand USB ports on macbook, and more. Two different converters for all your daily needs
- Next-Level 10Gbps & 3A Charging: No more slow 480Mbps, this usb to usb c adapter has a transfer speed of up to 10Gbps, allowing you to do more transferring in less time. This usb adapter fits both USB A and USB C charger, supporting up to 3A fast charging
- Upgraded Exquisite Craftsmanship: With an aluminum alloy housing and metal connector, the usbc to usb adapter is extremely durable and sturdy. Rigorously tested to withstand more than 10,000 times of plugging and unplugging, ensuring long-lasting performance
- Broad Compatible: The usb c to usb adapter widely supports all USB C/ USB A devices like laptops, tablets, cellphones, car chargers, and phone chargers. Such as compatible with MacBook Pro/Air 2023/2022, Thunderbolt 4/3 Devices,Apple MagSafe Watch 9/8/7/SE/Ultra, iPad Pro 2022/2021, Samsung Galaxy S23/S20/S10, and iPhone 17/16/15 Pro. Plug and play
- Please Note: To reach 10Gbps speed, keep the cable under 3.3 ft. For USB A Male to USB C adapters, try flipping the USB C connector. USB C Male to USB A adapters support bidirectional 10Gbps transfer within 3.3 ft
What changed in FDA labeling in 2025 and 2026?
Label changes are important, but a boxed-warning change is not a declaration that HT has no risks. The sequence and scope matter.
| Date | FDA action | How to interpret it |
|---|---|---|
| November 10, 2025 | FDA said it had requested labeling changes for menopausal hormone therapy products, including removal of specified boxed-warning statements about cardiovascular disease, breast cancer, and probable dementia, along with other proposed changes. | This was a request, not proof that every product label had already changed. |
| February 12, 2026 | FDA reported approving label changes for six products across systemic combination, systemic estrogen-alone, systemic progestogen-alone, and topical vaginal estrogen categories. For those products, the specified cardiovascular disease, breast cancer, and probable dementia statements were removed from the boxed warning. | The action was product-specific at that point. Check the current label for the exact medicine being considered. |
The Menopause Society’s November 2025 response emphasized that systemic estrogen still has potential risks for some individuals and that medical history and preferences must be reviewed. FDA labeling does not overturn the USPSTF recommendation against systemic HT for primary prevention of chronic conditions, and it does not establish HT as a heart-disease prevention medicine.
Are compounded “bioidentical” hormones safer?
Approved hormone products can be evaluated for dose, manufacturing quality, safety, and effectiveness. Custom-compounded products have not been shown to be safer or more effective. The Menopause Society warns that compounded preparations may have unpredictable absorption or dose and may lack adequate evidence on safety and effectiveness. “Bioidentical” is not, by itself, a safety credential.
Ask whether an approved product can meet the treatment goal before considering compounding. If a compounded medicine is proposed, request a clear explanation of why an approved option cannot be used and how dosing, quality, and monitoring will be handled.
Do these 3 things before closing this tab:
1Clear out junk files and repair common Windows errors2Scan for outdated or missing drivers - takes under a minute3Repair Windows errors before they cause bigger problemsWhat alternatives exist if you cannot or do not want to use hormones?
Nonhormone care for hot flashes and night sweats
The Menopause Society’s 2023 nonhormone therapy position statement is intended for people who cannot use HT or prefer not to. It reviews evidence-based prescription and behavioral approaches. Options can include nonhormonal medicines and structured behavioral interventions; the best choice depends on other conditions, current medicines, side effects, cost, and access. Supplements marketed for menopause are not automatically effective or safe, and “natural” does not mean interaction-free.
Best Value
- 5-in-1 Connectivity: Equipped with a 4K HDMI port, a 5 Gbps USB-C data port, two 5 Gbps USB-A ports, and a USB C 100W PD-IN port. Note: The USB C 100W PD-IN port supports only charging and does not support data transfer devices such as headphones or speakers.
- Powerful Pass-Through Charging: Supports up to 85W pass-through charging so you can power up your laptop while you use the hub. Note: Pass-through charging requires a charger (not included). Note: To achieve full power for iPad, we recommend using a 45W wall charger.
- Transfer Files in Seconds: Move files to and from your laptop at speeds of up to 5 Gbps via the USB-C and USB-A data ports. Note: The USB C 5Gbps Data port does not support video output.
- HD Display: Connect to the HDMI port to stream or mirror content to an external monitor in resolutions of up to 4K@30Hz. Note: The USB-C ports do not support video output.
- What You Get: Anker 332 USB-C Hub (5-in-1), welcome guide, our worry-free 18-month warranty, and friendly customer service.
Ask a clinician or pharmacist to match a nonhormone option to your symptom pattern and medical history. Do not replace an effective prescription with an untested supplement without discussing it.
Local treatment for genitourinary symptoms
For symptoms limited to vaginal or urinary tissues, low-dose vaginal estrogen is one local option. Other local prescription or nonprescription moisturizers and lubricants may help particular symptoms. A history of breast or uterine cancer should be discussed with the relevant specialist before any estrogen product is used.
Bone-loss and osteoporosis care
Bone-health alternatives are not simply a supplement list. Evaluation may include a dual-energy X-ray absorptiometry (DXA) scan, fracture-risk assessment, resistance and balance exercise, fall-risk reduction, adequate dietary calcium and vitamin D, and an osteoporosis medicine when indicated. ACOG’s osteoporosis guideline covers approved pharmacologic choices, monitoring, and follow-up. The right medicine depends on whether the goal is prevention in a person with risk factors or treatment of diagnosed osteoporosis.
A practical decision process to take to your clinician
- Define the goal. Write down whether you need relief from hot flashes, night sweats, sleep disruption, vaginal or urinary symptoms, bone-loss prevention, or treatment of a diagnosed condition. A goal of preventing heart disease alone is not an evidence-supported indication for systemic HT.
- Record timing and history. Note your age, date of the final menstrual period (if known), whether menopause was spontaneous, surgical, or unusually early, and any primary ovarian insufficiency diagnosis.
- Clarify uterus status. Bring the type and date of any hysterectomy or other gynecologic surgery. This determines whether endometrial protection with a progestogen is generally needed.
- Review risks and medicines. Discuss prior clots, stroke, coronary disease, migraine patterns, liver disease, unexplained bleeding, cancer history, blood pressure, smoking, diabetes, family history, and every prescription, over-the-counter medicine, and supplement.
- Compare route and regimen. Ask whether oral or transdermal estrogen is appropriate, what progestogen schedule protects the endometrium, and whether local vaginal treatment would meet the goal with less systemic exposure.
- Set a follow-up plan. Agree on the symptom target, dose, warning signs, when to reassess, and what would prompt a change. Reassessing does not mean there is an automatic stop date for every person; it means the indication and risks remain current.
- Make a bone plan when relevant. Ask whether you need DXA testing, fracture-risk calculation, exercise and fall-prevention guidance, or osteoporosis-specific medication.
Common mistakes to avoid
- Starting systemic HT solely because a friend, influencer, or advertisement calls it “heart protective.”
- Assuming a transdermal product is risk-free or that every vaginal product has the same systemic exposure.
- Using estrogen without adequate progestogen when a uterus is present.
- Treating a boxed-warning change as proof that all risks have disappeared.
- Using the WHI trial dose as a universal modern prescription.
- Choosing compounded hormones because “bioidentical” sounds safer.
- Stopping or changing treatment without a prescriber, especially after new bleeding, a clot, stroke symptoms, chest pain, or a cancer diagnosis.
How the evidence applies to different readers
| Reader situation | Evidence-informed focus |
|---|---|
| Healthy, symptomatic, younger than 60 or within 10 years of menopause | Discuss systemic HT for symptom relief, route and dose, uterus protection, and individual contraindications. The generally more favorable timing does not make therapy mandatory or risk-free. |
| Asymptomatic and considering HT only to prevent heart disease or dementia | Do not start systemic HT for that purpose; USPSTF recommends against it for primary prevention of chronic conditions. |
| Low bone density but no menopause symptoms | Obtain fracture-risk and bone-density evaluation and compare osteoporosis-specific medicines with other options. HT is not automatically the best treatment. |
| Premature ovarian insufficiency, early menopause, or surgical menopause | Seek individualized care because prolonged estrogen deficiency changes bone and cardiovascular considerations. Guidance often supports considering HT until around the average menopause age unless contraindicated. |
| Vaginal dryness or urinary symptoms without hot flashes | Discuss local vaginal treatment and nonhormonal moisturizers or lubricants rather than assuming systemic therapy is needed. |
| History of breast or uterine cancer, clot, stroke, liver disease, unexplained bleeding, or cardiovascular disease | Obtain specialist review before systemic HT; it may be unsuitable, and alternatives may be safer. |
The bottom line for heart and bone health
Hormone therapy can be an excellent, evidence-based treatment for bothersome menopause symptoms and can prevent bone loss and fractures while the treatment is used. It is not a general-purpose strategy to prevent heart disease or chronic illness in asymptomatic people. The safest decision is individualized: match the treatment to the goal, distinguish local from systemic exposure, protect the endometrium when a uterus is present, consider route and dose, and revisit the plan as health and preferences change.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
